{"id":"W4283453063","doi":"10.1016/j.jtho.2022.05.016","title":"Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Janssen Pharmaceuticals; Chugai Pharmaceutical; Merck Sharp and Dohme; Genentech; Eisai; G1 Therapeutics; Puma Biotechnology; Yuhan; BeiGene; Mirati Therapeutics; Clovis Oncology; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; F. Hoffmann-La Roche; Takeda Pharmaceutical Company; AbbVie; Teva Pharmaceutical Industries; Boehringer Ingelheim Japan; Merck KGaA; Daiichi Sankyo Europe; National Cancer Institute; Bayer; Gilead Sciences; Roche; Novartis; Mesothelioma Applied Research Foundation; GlaxoSmithKline; Canadian Asian Studies Association; AstraZeneca; Ono Pharmaceutical; U.S. Department of Defense; Eli Lilly and Company; Bristol-Myers Squibb; Kyowa Hakko Kirin; Sanofi; Amgen; Boehringer Ingelheim; Pfizer","keywords":"Atezolizumab; Medicine; Placebo; Maintenance therapy; Hazard ratio; Internal medicine; Oncology; Carboplatin; Population; Chemotherapy; Cancer; Confidence interval; Immunotherapy; Pembrolizumab; Pathology; Cisplatin","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007745762,0.0001742292,0.001196269,0.000654767,0.0001017225,0.000006906214,0.0001142029,0.00005372422,0.00006629497],"category_scores_gemma":[0.0002051629,0.0001112406,0.00009816038,0.001242351,0.0002547707,0.0000909308,0.00009986519,0.0005522243,1.218234e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001081913,"about_ca_system_score_gemma":0.0007485719,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002362521,"about_ca_topic_score_gemma":0.0008003418,"domain_scores_codex":[0.9978124,0.000266988,0.0007091488,0.000253816,0.0006783066,0.0002793024],"domain_scores_gemma":[0.997425,0.0001987268,0.001064004,0.0002773844,0.0009000959,0.000134831],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0598579,0.0009049418,0.8910445,0.0001204373,0.004148257,0.00982878,0.003359763,0.006079557,0.0002415878,0.000004352982,0.000389253,0.0240207],"study_design_scores_gemma":[0.01029907,0.02551055,0.9562706,0.0002490102,0.001236824,0.0005336207,0.002002485,0.0004497162,0.0003604086,0.00001034953,0.002910782,0.0001665189],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9963266,0.001304983,0.00005381338,0.001575709,0.00005256557,0.0004210827,0.00002754927,0.000007257467,0.0002303981],"genre_scores_gemma":[0.9982288,0.0005999359,0.0005410364,0.0002110465,0.00003623793,0.00003105658,0.00001623053,0.000022747,0.000312946],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06522618,"threshold_uncertainty_score":0.4536258,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02566415558250009,"score_gpt":0.377302734165158,"score_spread":0.351638578582658,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}